4 completed, 2 terminated, 1 no longer available. 3 Phase 2, 2 Phase 1, 2 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 3 | Completed 2, Terminated 1 |
| Phase 1 | 2 | Completed 1, Terminated 1 |
| Phase 3 | 2 | Completed 1, Terminated 1 |
Follow eryaspase: new trials by email Literature Review of eryaspase trials Research Report on eryaspase
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Eryaspase With Modified FOLFIRINOX in Advanced Pancreatic Ductal Adenocarcinoma Eryaspase, FOLFIRINOX - Locally Advanced Pancreatic Ductal Adenocarcinoma, Metastatic Pancreatic Ductal Adenocarcinoma | Phase 1 | Completed | Georgetown University | 19 | 2020-12-02 | 2025-06-11 |
| Study of Eryaspase in Combination With Chemotherapy Versus Chemotherapy Alone for the Treatment of TNBC (TRYbeCA-2) eryaspase (L-asparaginase encapsulated in red blood cells), Gemcitabine, Carboplatin - Triple Negative Breast Cancer | Phase 2 / Phase 3 | Terminated | ERYtech Pharma | 27 | 2019-06-13 | 2022-08-01 |
| Study of Eryaspase in Combination With Chemotherapy Versus Chemotherapy Alone as 2nd-Line Treatment in PAC eryaspase, Gemcitabine plus Abraxane, Irinotecan plus 5-FU plus leucovorin - Pancreatic Adenocarcinoma | Phase 3 | Completed | ERYtech Pharma | 512 | 2018-09-15 | 2022-10-18 |
| Asparaginase Encapsulated in Erythrocytes for Patients With ALL and Hypersensitivity to PEG-asparaginase GRASPA - Acute Lymphoblastic Leukemia | Phase 2 | Completed | Birgitte Klug Albertsen | 55 | 2017-08-23 | 2024-03-15 |
| L-asparaginase Encapsulated in Red Blood Cells (Eryaspase) for Treatment of Adult Patients With ALL or LBL L-asparaginase encapsulated in RBC - Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma | Phase 1 | Terminated | ERYtech Pharma | 14 | 2013-10-01 | 2018-07-05 |
| GRASPA Treatment for Patients With Acute Myeloblastic Leukemia GRASPA - Acute Myeloid Leukemia | Phase 2 | Completed | ERYtech Pharma | 123 | 2013-02-01 | 2022-02-21 |
| Expanded Access Program: Safety of Erythrocytes Encapsulating L-asparaginase (GRASPA®) in Combination With Polychemotherapy in Patients Under 55 Years Old With Acute Lymphoblastic Leukemia (ALL) at Risk to Receive Other Formulation of Asparaginase suspension of erythrocytes encapsulating L-asparaginase - Acute Lymphoblastic Leukemia | No longer available | ERYtech Pharma | 2018-12-04 |
Precursor Cell Lymphoblastic Leukemia-Lymphoma (3) · Leukemia (2) · Leukemia, Myeloid, Acute (1) · Lymphoma (1) · Neoplasms (1) · Triple Negative Breast Neoplasms (1)
ERYtech Pharma (5) · Birgitte Klug Albertsen (1) · Georgetown University (1)
France (3) · United States (3) · Belgium (1) · Denmark (1) · Estonia (1) · Finland (1) · Hungary (1) · Lithuania (1) · Norway (1) · Spain (1) · Sweden (1) · United Kingdom (1)
Brigitte Klug Albertsen, MD, PhD (1) · Manuel Hidalgo, MD, PhD (1) · Marcus S Noel, MD (1) · Pascal Hammel, MD, PhD (1) · X Thomas, Doctor (1)
2016 (1)